We serve Chemical Name:ethyl 4-methylpyridine-2-carboxylate CAS:58997-09-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:ethyl 4-methylpyridine-2-carboxylate
CAS.NO:58997-09-4
Synonyms:ethyl 4-methypicolinate;4-Methyl-pyridin-carbonsaeure-(2)-ethylester;ethyl 4-methyl-2-pyridinecarboxylate;4-Methyl-picolinsaeure-ethylester;Ethyl 4-methylpicolinate;4-Methylpyridine-2-carboxylic acid ethyl ester;2-Ethoxycarbonyl-4-methylpyridin;4-Methyl-pyridin-2-carbonsaeure-aethylester
Molecular Formula:C9H11NO2
Molecular Weight:165.18900
HS Code:2933399090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:275.8ºC at 760 mmHg
Density:1.077g/cm3
Index of Refraction:1.506
PSA:39.19000
Exact Mass:165.07900
LogP:1.56670
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like ethyl 4-methypicolinate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-Methyl-pyridin-2-carbonsaeure-aethylester physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Ethyl 4-methylpicolinate Use and application,4-Methylpyridine-2-carboxylic acid ethyl ester technical grade,usp/ep/jp grade.
Related News: From the perspective of the overall life cycle of generic drugs from R & D to sales, with the expiration of patents, the business model for the production and marketing of generic pharmaceutical raw materials has changed, demand has increased, business potential has been realized quickly, and gross profit margins have shown a downward trend. ethyl 4-methylpyridine-2-carboxylate manufacturer It wasn’t known if this was due to racial differences in breast cancer-related genetic mutations, making it unclear whether race should help guide genetic testing. ethyl 4-methylpyridine-2-carboxylate supplier From the perspective of the overall life cycle of generic drugs from R & D to sales, with the expiration of patents, the business model for the production and marketing of generic pharmaceutical raw materials has changed, demand has increased, business potential has been realized quickly, and gross profit margins have shown a downward trend. ethyl 4-methylpyridine-2-carboxylate vendor It wasn’t known if this was due to racial differences in breast cancer-related genetic mutations, making it unclear whether race should help guide genetic testing. ethyl 4-methylpyridine-2-carboxylate factory Lilly did show much more conclusively that donanemab, which zeroes in on amyloid plaques, does reduce levels of the aggregates of misfolded proteins in the brain. This is what Biogen also showed with Aduhelm, and it turned out this week to be enough for a full FDA approval, hence the stock bump for Lilly.
